Drugs / Cepharanthine
Cepharanthine
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT05398705 | May → Aug 2022 | viral infectious disease | Shanghai Jiao Tong University School of Medicine | Completed | Missed primary |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Cepharanthine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05398705 ↗ |
| Known as | CEP | “Cepharanthine (CEP) is a natural remedy that potently inhibits SARS-CoV-2 activity both in vitro and in vivo.” PMID 39890847 ↗ Jan 2025 |
| Known as | NSC-623442 | ChEMBL registry synonym — accepted as the source's own label CHEMBL449782 ↗ |
| Action | Inhibit | “potently inhibits SARS-CoV-2 activity both in vitro and in vivo” PMID 39890847 ↗ Jan 2025 |
| Modality | Small molecule | — CHEMBL449782 ↗ |